인터랙티브 브레이크아웃 디스커션

브레이크아웃 디스커션은 승인제 비공식 디스커션으로, 특정 토픽에 대해 아이디어 및 경험을 교환하고, 향후 협업을 발전시킬 수 있습니다. 각 디스커션은 퍼실리테이터가 주도하며, 디스커션의 진행과 그룹 활성화를 도모합니다. 이 형식을 최대한으로 활용하기 위해 자신의 연구 사례를 공유하고, 집단에서의 문제 해결 세션에 참가하고, 활발한 아이디어 공유를 준비해주시기 바랍니다.

모든 브레이크아웃 디스커션은 대면으로만 진행됩니다.

Bi & Multispecific Engineering
Bi and Multispecific T Cell Engagers in an Era of Increased Awareness of Tumor and Patient Heterogeneity
Moderator: Siddhartha Roychoudhury, PhD, Asset Leader, Immuno-Oncology Development, Astellas Pharma

How do we go about selecting the right tumors for the right MOA?
How can we explore novel approaches to MOA-driven patient enrichment?
How can we develop options for rational combinations?

Breakthroughs in Cell Therapy
New Opportunities to Promote Tumor Antigen Presentation through Myeloid Cell Therapies
Moderator: Warren Anderson, PhD, Scientist III, Immunology, Inceptor Bio

Recent technological advances have made concepts like tumor vaccines or transgenic TCRs more promising than ever. Can myeloid cell therapies perform similarly with reduced labor and cost?
What have we learned thus far about the practical limitations of generating myeloid-based cell therapies? What has succeeded?
Considering the successes of CAR Ts or T-cell directed therapies, how should we approach the idea of myeloid based cell therapies? Competitor or teammate?

Bridging Science and Support: Integrative Strategies in Cell Therapy
Moderator: David James, Resident Physician, Ric Scalzo Institute for Botanical Research, Naturopathic Specialists LLC

Exploring how integrative and naturopathic oncology can support patients undergoing advanced immune therapies such as CAR T-cell, bispecific antibodies, NK cell vaccines, and dendritic cell therapy
Clinical applications for monitoring immune therapy response and toxicity using biomarkers and interleukin profiling (e.g., IL-6, IL-8, IL-1β, VEGF, MMP9, TNF-α) from a patient-centered lens
Practical strategies for managing treatment-related adverse events (cytokine release syndrome, neurotoxicity, fatigue) through evidence-informed supportive care
Shared decision-making models to align complex therapies with patient values and quality-of-life goals
Real-world insights into harmonizing conventional protocols with integrative care to improve outcomes and experience

Translating Multispecific Success
What Are We after with Bispecific Targeting of Solid Tumors?
Moderator: Tatiana Novobrantseva, PhD, CSO, NextPoint Therapeutics

What unmet need is driving bispecific targeting? Efficacy? Width of applicability? Safety? What strategies are needed?
Is there a special place for biparatopic targeting?
Is companion diagnostic a must-have for developing bispecific targeting? Does it need to be quantitative?
Bispecific versus combination: major pros and cons

Autoimmunity
Learnings from I-O for I&I
Moderator: Marc A. Gavin, PhD, Senior Research Fellow & Head, Immunology, InduPro

Depleting pathogenic immune cells: Will TCEs be as potent as CAR T, within tolerated dose windows?
KIR+ CD8 Tregs: Do they respond to current therapies, and does it matter?
Agonizing cytokine receptors: Do feedback mechanisms make it too complicated?

Precision Targeting of Autoimmune B Cells with Chimeric Antigen Receptor T Cells
Moderator: Marco Ruella, MD, Assistant Professor, Scientific Director, Hematology and Oncology and Center for Cellular Immunotherapies, University of Pennsylvania

How to interpret small pilot trials of CAR T or bispecifics in SLE and autoimmunity
Role of lymphodepletion regimens
Long-term efficacy and potential toxicities?

Antibody-Drug Conjugates
Selecting ADC Design Features for a Specific Target and Indication
Moderator: Ian Nessler, PhD, Senior Scientist II, Quantitative, Translational, and ADME Sciences, AbbVie

Target Characterization: Expression and Internalization Profile
Design Considerations for Heme vs. Solid Tumor Indications
Payload Selection (Bystander vs. Non-Bystander Payloads)
Future Directions and Novel ADC Formats

Innate Immunity
Translating in vitro Immuno-Oncology Models to in vivo Impact
Moderator: Craig Thalhauser, PhD, Senior Director, Clinical Pharmacology & Quantitative Sciences, Genmab US Inc

What limits current in vitro models from accurately reflecting the complex tumor microenvironment and in vivo bispecific antibody activity?
Designing in vitro assays that better predict targeted efficacy and potential for off-target effects within the TME
Innovative in vitro approaches or technologies that hold promise for predicting the in vivo behavior and therapeutic potential of bispecific antibodies in immuno-oncology?

Practical Applications for Spatial Biology in Immuno-Oncology
Moderator: Hao Lo, PhD, Research Scientist, Translational Medicine, Amgen

Spatial biology has recently exploded-during what stages of IO drug discovery are you using spatial biology and what questions are you answering?
Spatial biology is a new frontier and is constantly evolving-how do you balance ever-pursuing the latest technologies, versus committing to and developing specific technologies?
Integration of spatial biology into IO drug discovery can require huge investments of computational, wet-lab, and financial resources-what are the biggest hurdles you’re encountering, and how are you navigating these challenges?

* 주최측 사정에 따라 사전 예고없이 프로그램이 변경될 수 있습니다.

해당 컨퍼런스는 종료되었습니다.

Choose your language